The Hidden Cycle of Diabetes Medication
For millions of adults living with type 2 diabetes mellitus (T2DM), starting a course of GLP-1 receptor agonists (GLP-1 RAs) represents a significant turning point in their health journey. Whether prescribed as Ozempic, Wegovy, Mounjaro, or Zepbound, these injectable therapies offer powerful tools for managing blood sugar and promoting weight loss. However, the path to metabolic stability is rarely linear.
A compelling new analysis presented at ENDO 2026, the annual meeting of the Endocrine Society held in Chicago this June, sheds fresh light on the real-world trajectory of patients taking these potent medications. Contrary to the assumption that discontinuation signals a permanent abandonment of treatment, the study suggests a more nuanced "start-and-stop" reality. According to Sainikhil Sontha, lead researcher from Boston University, many patients view medication breaks not as failures, but as temporary pauses driven by external factors or manageable side effects.
Understanding the Stop-and-Start Trend
The study examined a massive cohort of 60,222 adults aged 18 to 64 who had initiated treatment with liraglutide, semaglutide, or tirzepatide. Using retrospective claims data spanning from January 2019 to June 2025, researchers tracked two critical behaviors: initial discontinuation and subsequent reinitiation.
The findings paint a clear picture of attrition followed by recovery. By the end of one year, approximately 41.5 percent of patients had stopped their therapy. This number climbed to 58.0 percent by the second year. While these numbers initially suggest poor adherence, the most striking statistic lies in what happens next. Of the nearly 15,000 patients who dropped out, more than half—specifically 53.6 percent—returned to their medication within just 12 months. Two years out, that number rose to 65.9 percent.
This data challenges the narrative that once a patient stops their GLP-1, they stay off. Instead, it indicates that interruptions are common, yet re-engagement with care is a resilient pattern. This insight is crucial for clinicians designing long-term management plans that anticipate fluctuations in adherence.
Comparing Retention Rates Across Medications
Not all medications are created equal when it comes to long-term use. The study provided a comparative risk assessment between the three major classes of injectables available during the observation period: liraglutide, semaglutide, and tirzepatide.
Patients prescribed liraglutide served as the baseline for comparison. Those on semaglutide (often associated with brand names like Ozempic or Wegovy) demonstrated a substantially lower risk of discontinuation. However, the strongest retention performance came from patients prescribed tirzepatide (brands including Mounjaro and Zepbound).
- Semaglutide: Associated with a 28 percent lower risk of stopping compared to liraglutide.
- Tirzepatide: Showed the lowest risk, with a 41 percent reduction in discontinuation hazards.
These statistics suggest that newer dual-agents or potent single agents may offer better tolerability profiles or efficacy milestones that encourage persistence.
Trial Comparison: Discontinuation Risks
| Factor | Group | Hazard Ratio (HR) | Interpretation |
|---|---|---|---|
| Medication Type | Liraglutide (Reference) | 1.00 | Baseline risk |
| Semaglutide | 0.72 | Lower risk of stopping | |
| Tirzepatide | 0.59 | Much lower risk of stopping | |
| Coverage | Private Insurance | 1.00 | Baseline risk |
| Medicare/Medicaid | 1.17 - 1.18 | Higher risk of stopping | |
| Demographics | Black or African American | 1.17 | Higher risk of stopping |
| Outcomes | Weight Loss ≥5% | 0.90 - 0.91 | Lower risk of stopping |
The Impact of Insurance and Access
While clinical efficacy plays a role in sticking with treatment, economic accessibility remains a dominant barrier. The study highlighted significant disparities linked to insurance coverage. Patients covered by Medicaid or Medicare faced a higher risk of discontinuing their prescriptions compared to those with private insurance.
This trend persisted even when considering the decision to return to treatment. These same insured populations were less likely to reinitiate therapy after stopping. This underscores a systemic issue where high deductibles, formulary gaps, or lack of prior authorization support prevent patients from maintaining continuity of care.
